DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Betaseron (Interferon Beta-1B) - Published Studies

 
 



Betaseron Related Published Studies

Well-designed clinical trials related to Betaseron (Interferon Beta-1B)

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. [2014]

Interferon beta for secondary progressive multiple sclerosis. [2012]

Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. [2011.08.30]

Interferon beta-1b and glatiramer acetate effects on permanent black hole evolution. [2011.04.05]

[Interferon beta for multiple sclerosis. How much is good enough?]. [2010.12]

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. [2010.06.08]

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. [2010.04]

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010]

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology. [2009.12.14]

Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. [2009.12]

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate. [2009.12]

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [2009.10]

A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [2009.09.29]

Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. [2009.08]

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. [2008.08.13]

Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. [2008.06.17]

Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. [2008.04]

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. [2007.09]

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. [2007.08.04]

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. [2006.10.10]

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. [2006.04.11]

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab. [2006.02]

Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis. [2006.01]

Response to interferon beta-1a treatment in African American multiple sclerosis patients. [2005.11]

Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. [2005.05]

Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of interferon beta-1b in patients with secondary progressive multiple sclerosis. [2005.05]

Interferon beta-1b treatment does not induce autoantibodies. [2005.03.22]

Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. [2005.02.22]

Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. [2004.12]

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. [2004.11.23]

Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. [2004.06]

Lymphocyte subpopulations, oxidative burst and apoptosis in peripheral blood cells of patients with multiple sclerosis-effect of interferon-beta. [2003.08]

The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. [2003.03.11]

Interferon beta-1a in primary progressive multiple sclerosis. [2003.02.15]

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. [2003.01.14]

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). [2002.04.27]

A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). [2002.04.01]

Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. [2001.12.26]

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. [2001.11.27]

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. [2001.07]

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. [2001.03]

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group. [2000.06]

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. [2000.01.11]

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. [1999.12]

[Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis] [1999.08]

Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. [1999.06.10]

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. [1999.04.12]

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B. [1999.01.15]

Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. [1998.11]

Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. [1998.10]

Interferon beta-1b: latest published results, 1995. [1996.07]

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. [1996.06]

Betaseron: the new MS treatment. [1994.02]

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. [1993.10]

Phase II trials of interferons-alpha and -beta in advanced sarcomas. [1992.12]

Otologic effects of interferon beta serine in experimental rhinovirus colds. [1992.09]

Biological and clinical effects of interferon-beta ser at two doses. [1990.12]

Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds. [1989.10]

Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. [1988.07]

Well-designed clinical trials possibly related to Betaseron (Interferon Beta-1B)

Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. [2011.04]

Long-term follow-up of clinical trials of multiple sclerosis therapies. [2011.01.04]

The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. [2010.03]

A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.11.10]

Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. [2009.11.03]

Serum levels of CXCL13 are elevated in active multiple sclerosis. [2009.11]

A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [2009.09.30]

Adverse drug reactions after 24-month treatment with two-dosage regimens of betaferon in patients with multiple sclerosis. [2009.07]

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. [2009.06.09]

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. [2009.05.20]

Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. [2008.08]

Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. [2008.08]

A clinical study of multiple sclerosis patients treated with betaferon. [2008.07]

Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. [2008.05]

Adherence to therapy: using an evidence-based protocol. [2007.11]

Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. [2007.08]

Lack of association between antimyelin antibodies and progression to multiple sclerosis. [2007.01.25]

Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. [2006.05]

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b. [2003.05.13]

Randomized controlled trials to assess therapies for multiple sclerosis. [2002.04.23]

Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. [2002.01]

The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. [2001.12.26]

Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. [2001.12.11]

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. [1998.12]

Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques. [1998.07]

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS. [1998.06]

IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. [1997.06]

Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. [1995.10]

Other research related to Betaseron (Interferon Beta-1B)

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. [2011.12]

Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis: Five-Year Clinical Trial Follow-up. [2011.11]

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. [2011.09.30]

Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. [2011.05.26]

Predictive factors of neutralizing antibodies development in relapsing-remitting multiple sclerosis patients on interferon Beta-1b therapy. [2011.04]

Interferon therapy in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of the comparative trials. [2011.03.15]

Interferon-beta-1b: a review of its use in multiple sclerosis. [2011.01.01]

Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. [2011]

Therapeutic efficacy of interferon beta-1b in Japanese patients with optic-spinal multiple sclerosis. [2011]

Apolipoprotein alleles and the response to interferon-beta-1b in multiple sclerosis. [2011]

PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. [2010.10]

A meta-analysis of the efficacy and tolerability of interferon-beta in multiple sclerosis, overall and by drug and disease type. [2010.10]

Fatigue and cognition in patients with relapsing multiple sclerosis treated with interferon beta. [2010.10]

Persistent interferon-ss-1b-induced psychosis in a patient with multiple sclerosis. [2010.10]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014